To amend title XI of the Social Security Act to enhance pharmacy benefit manager transparency requirements.
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™H.R. 7717 is a bill introduced in the 118th Congress aimed at amending title XI of the Social Security Act to enhance transparency requirements for pharmacy benefit managers (PBMs). The bill seeks to increase disclosure and oversight of PBM activities, which play a significant role in managing prescription drug benefits. The bill was referred to the Subcommittee on Health but has since failed or expired. No full text or official summary is available to provide detailed provisions.
This bill intended to improve transparency in pharmacy benefit management but did not advance beyond subcommittee referral and ultimately expired without enactment.
- The bill targets amendments to title XI of the Social Security Act focused on PBM transparency.
- It was introduced in the House and referred to the Subcommittee on Health on December 17, 2024.
- The bill status is 'Failed / Expired,' indicating it did not progress to law during the 118th Congress.
['Patients and consumers seeking clearer information on pharmacy benefit management.', 'Health policymakers and regulators aiming for enhanced oversight of PBMs.', 'Potentially health insurers and pharmacies affected by PBM practices.']
['Lack of available full bill text limits understanding of specific transparency requirements and enforcement mechanisms.', 'Implementation challenges could arise depending on the scope of disclosure and regulatory authority granted.', 'Potential administrative costs for PBMs and oversight agencies to comply with new transparency mandates.']
The bill was introduced during the 118th Congress and referred to a relevant subcommittee but did not advance further. It falls within the health policy area, focusing on prescription drug benefit management, a topic of ongoing legislative interest. No additional legislative actions or companion measures are noted.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Enhanced transparency requirements could lead to increased administrative burden on PBMs and regulators.', 'Improved disclosure might influence drug pricing negotiations and insurance plan designs indirectly.', 'Greater public and policymaker awareness of PBM operations could affect future legislative or regulatory initiatives.']
Due to the absence of the full bill text and official summary, transparency and oversight assessments are limited. The bill's referral to a subcommittee without further action suggests limited legislative momentum. Future efforts to enhance PBM transparency would benefit from clear, accessible documentation to facilitate public understanding and informed oversight.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.